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Hypoxia, which characterizes most tumor tissues, can alter the function of different
immune cell types, favoring tumor escape mechanisms. In this study, we show that
hypoxia profoundly acts on NK cells by influencing their transcriptome, affecting their
immunoregulatory functions, and changing the chemotactic responses of different
NK cell subsets. Exposure of human peripheral blood NK cells to hypoxia for
16 or 96 h caused significant changes in the expression of 729 or 1,100 genes,
respectively. Gene Set Enrichment Analysis demonstrated that these changes followed
a consensus hypoxia transcriptional profile. As assessed by Gene Ontology annotation,
hypoxia-targeted genes were implicated in several biological processes: metabolism, cell
cycle, differentiation, apoptosis, cell stress, and cytoskeleton organization. The hypoxic
transcriptome also showed changes in genes with immunological relevance including
those coding for proinflammatory cytokines, chemokines, and chemokine-receptors.
Quantitative RT-PCR analysis confirmed the modulation of several immune-related
genes, prompting further immunophenotypic and functional studies. Multiplex ELISA
demonstrated that hypoxia could variably reduce NK cell ability to release IFNγ, TNFα,
GM-CSF, CCL3, and CCL5 following PMA+Ionomycin or IL15+IL18 stimulation, while it
poorly affected the response to IL12+IL18. Cytofluorimetric analysis showed that hypoxia
could influence NK chemokine receptor pattern by sustaining the expression of CCR7
and CXCR4. Remarkably, this effect occurred selectively (CCR7) or preferentially (CXCR4)
on CD56bright NK cells, which indeed showed higher chemotaxis to CCL19, CCL21, or
CXCL12. Collectively, our data suggest that the hypoxic environment may profoundly
influence the nature of the NK cell infiltrate and its effects on immune-mediated responses
within tumor tissues.
Keywords: NK cells, hypoxia, tumor immunology, cytokines/chemokines, chemokine receptors, CD56bright cells,
tumor infiltration, transcriptome
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INTRODUCTION
NK cells are powerful effectors of the innate immunity with
anti-tumor activity (1–5). They are endowed with a unique
pattern of receptors sensing changes in MHC-I expression
levels (which are often decreased in tumor cells) or recognizing
ligands induced by tumor transformation, cell stress, and DNA
damage (1, 5–8). By these receptors NK cells can direct their
potent lytic machinery to target and eliminate many tumor cell
types (6). In addition, NK cells can release pro-inflammatory
cytokines and various chemotactic factors (IFNγ, TNFα, GM-
CSF, CCL3/CCL4) potentially amplifying immune responses to
the tumor (1, 6, 9–11). The cytolytic function and the capability
of releasing cytokines and chemokines appear to be differently
represented in the two major subsets of peripheral blood (PB)-
NK cells, characterized by the CD56dim/CD16bright (CD56dim) or
the CD56bright/CD16dim/neg (CD56bright) phenotype (1, 12–14).
The CD56dim cells are strongly cytotoxic and can also produce
cytokines in response to specific stimuli. These cells represent
the large majority of the PB-NK cell population and express
chemokine receptors, mainly CXCR1 and CX3CR1, that enable
their recruitment to inflamed tissues (1, 9, 11, 15, 16). Conversely,
CD56bright cells are poorly cytotoxic and release high amount
of cytokines, especially in response to monokines. According
to their expression of CCR7 and CD62L, these cells are mainly
located within secondary lymphoid compartments while they
account for only 10% of PB-NK cells (1, 9, 11, 15).
The increasing interest on NK cells as potential tools for
immunotherapy has recently inspired many studies aimed
at defining how their anti-tumor activity can be influenced
by the tumor microenvironment. Along this line, different
suppressive interactions mediated by tumor cells, tumor-
associated fibroblasts, or regulatory immune cells have been
described and characterized (17–22). In addition, it has been
shown that tumor cells can escape NK cell attack by modulating
the surface expression of various NK-receptor ligands (2, 23–27).
In spite of these important advances in the field, a crucial issue
that still remains to be investigated for an effective exploitation
of NK cells in the therapy of solid tumors is the recruitment of
NK cells to tumor tissues. Few recent studies have shown that
higher NK cell infiltration correlates with a better prognosis of
the disease (23, 28, 29), but have also indicated that the NK cell
infiltrate in tumor tissues is often poor and, in some cases, mostly
represented by poorly cytotoxic CD56bright cells (5, 30, 31).
Specific chemokine milieus, or alteration of chemokine receptor
patterns, may account for these findings. However, an exhaustive
explanation on how the tumor microenvironment can influence
NK cell infiltration has not yet been achieved.
Reduced partial O2 tension (pO2, 0–20mm Hg, hypoxia),
which often affects tumor tissues, may play role in this context.
Abbreviations: PB, peripheral blood; pO2, low oxygen tension; GSEA, Gene
Set Enrichment Analysis; qRT-PCR, Real time PCR; Hy-NK, hypoxic NK cells;
HIF, hypoxia-inducible factor; NES, normalized enrichment score; FDR q-val,
false discovery rate q-values; NOM p-val, nominal p-values; LEA, Leading
Edge Analysis; GO, gene ontology; HMGs, hypoxia-modulated genes; MDMs,
monocyte-derived macrophages; iDCs, immature DCs; mDCs, mature DCs;
IONO, ionomycin.
Hypoxia is an important driver of malignant progression and
resistance to therapy (23, 32, 33). It can influence the function
of different cell types within the tumor lesion and affect the
recruitment of immune cells, favoring tumor escape mechanisms
(33). Indeed, exposure to hypoxia can induce different immune
and non-immune cells to change the expression of pro-
angiogenetic factors, cytokines, and chemokines (including
VEGF, SPP1, IL-1β, MIF, CXCL12, and CXCL8), or chemokine
receptors (including CXCR4, CCR2, and CCR5) (34–38). In spite
of many studies on this issue, limited information is currently
available on the impact of hypoxia on NK cells and their subsets,
notably on their ability to respond to specific chemotactic stimuli
or to release immune-active soluble factors (39–41). We have
previously shown that, in NK cells exposed to IL-2, hypoxia
can down-regulate expression and function of most NK cell
receptors that activate cytolytic activity against tumor or virally
infected cells, but preserves NK cell ability to kill targets via
ADCC (39), suggesting that NK cells may be effective even in
hypoxic niches in the context of combined immunotherapeutic
approaches. In this study, we integrate previous data and provide
an overview of the effect of hypoxia on NK cells stimulated with
IL-2. Moreover, we indicate some clues on how the composition
and the function of NK cell infiltrate may be influenced by the
hypoxic environment in tumor tissues.
MATERIALS AND METHODS
NK Cells Isolation and Culture
NK cells were obtained from PB of healthy donors provided
by the transfusion center of the Ospedale Policlinico San
Martino following approved internal operational procedures
(IOH78). Written informed consent from the donors was
provided according to the Declaration of Helsinki. Briefly: NK
cells from healthy donors were isolated from PB mononuclear
cells using RosetteSep NK Cell Enrichment Cocktail (StemCell
Technologies, 15025 Vancouver, Canada). Only preparations
displaying more than 95% of CD56+ CD3– CD14– NK cells
were selected for the experiments. After isolation, NK cells
were cultured for the indicated time points in RPMI 1640
(Lonza Verviers, Belgium) supplemented with 10% Fetal Bovine
Serum (FBS, Voden Medical S.p.a. Meda MB, Italy), antibiotic
mixture (0.05 mg/mL penicillin, 0.05 mg/mL streptomycin
Lonza, Verviers, Belgium), and 100 U/mL recombinant human
IL-2 (Proleukin, Novartis Basilea, Switzerland) at 2X 106cells/mL
in round bottom 96-well microtiter plates. The cultures
were performed either under normoxic conditions in a
humidified incubator containing 20% O2, 5% CO2, and 75%
N2 or under hypoxic conditions. Hypoxic conditions were
obtained by culturing cells in a sealed anaerobic workstation
incubator (Ruskinn, INVIVO2 400, CARLI Biotec, Roma, Italy),
incorporating a gas mixing system (Ruskinn Gas Mixer Q)
and flushed with a mixture of 1% O2, 5% CO2, and 94%
N2.
RNA Isolation and cRNA Synthesis
Total RNA was purified from NK cells derived from three
healthy donors using the RNeasy MiniKit from Qiagen (Milano,
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Italy). RNA was controlled for integrity by nanoelectrophoresis
with an Agilent 2100 Bioanalyzer (Agilent Technologies Europe,
Waldbroon, Germany), quantified by spectrophotometry using
a NanoDrop ND-1000 (NanoDrop Technologies, Wilmington,
USA), and reverse-transcribed into double-stranded cDNA
on a GeneAmp PCR System 2700 thermal cycler (Applied
Biosystems, Milano) using the one-cycle cDNA synthesis kit
(Affymetrix, Milano). cDNA derived from three donors/time
point was purified and biotin labeled using the GeneChip IVT
kit (Affymetrix). Labeled cRNA was fragmented according to
Affymetrix’s instructions.
GeneChip Hybridization and Array Data
Analysis
Gene expression profiling was performed as described previously
(42). Briefly, Fragmented cRNAwas hybridized on the Affymetrix
HG-U133 plus 2.0 GeneChips (Genopolis Corporation, Milano)
containing 54,000 probe sets (coding for 47,000 transcripts
and variants, including 38,500 unique human genes) on a
single array. Chips were stained with streptavidin-phycoerythrin
(Invitrogen Life Technologies, Milano) and scanned using
an Affymetrix GeneChip Scanner 3000, as described. Data
were processed by RMA normalization utilizing the “Affy” R
package. Statistical analysis using paired t-test was performed
to identify differentially expressed genes. We corrected the p-
value for multiple hypothesis testing by Benjamini–Hochberg
method to false discovery rate control. Only gene differences
that passed the test at a confidence level of 95% (P <
0.05) and a false discovery rate of 0.05% were considered
significant. Fold-change (FC) was calculated as the ratio
between the average expression level under hypoxia and
normoxia. Genes were defined as being differentially regulated
by hypoxia if they exhibited more than 2-fold increase in
gene expression or down-regulated if they showed <0.5-fold
change compared with normoxic cultures. We converted the
Affymetrix probe sets into the corresponding gene symbol
by Netaffx tool. When multiple probe sets were associated
with the same gene symbol, the probe set with the highest
expression signal was considered. The full set of data from
each microarray experiment has been deposited in the Gene
Expression Omnibus public repository at NCBI (www.ncbi.nlm.
nih.gov) and is accessible through GEO (Accession number
GSE116660). Biological processes were assessed by DAVID Gene
Ontology (GO) enrichment analysis (http://david.niaid.nih.gov).
The significant GO terms were defined as p < 0.05 and FDR <
0.05.
Gene Set Enrichment Analysis
Gene Set Enrichment Analysis (GSEA) was performed on all
probe sets of the Affymetrix HG-U133 Plus 2.0 GeneChip, as
described previously (43). An enrichment score (ES) and a
normalized enrichment score (NES) were calculated for every
gene set. The statistical significance of NES was estimated by
an empirical test using 1,000 gene set permutations to obtain
the nominal p-value. A false discovery rate (FDR) q value was
estimated to control the probability that a NES could represent a
false positive finding. The gene sets used in the GSEA belong to
the C2.CGP collection of the Broad Institute Molecular Signature
v5 Database (MSigDB) (44). The analysis used Signal-to-Noise
metric and considered gene sets containing at least 15 and up
to 250 probe sets. An enrichment with FDR q-values lower than
0.05 and nominal p < 0.05 was considered significant. Leading
Edge Analysis (LEA) of enriched gene sets was used to identify
key genes related to NK response to hypoxia.
Real-Time RT-PCR
cDNA was prepared from purified total RNA using SuperScript
Double-Stranded cDNA synthesis kit (Invitrogen). Real time
PCR (qRT-PCR) was performed on a 7500 Real Time PCR System
(Applied) in triplicate for each target transcript using SYBR
Green PCR Master Mix and sense/antisense oligonucleotide
primers synthesized by TIBMolbiol (Genova) or purchased
from Quiagen, as detailed before (45). Expression data were
normalized on the values obtained in parallel for three reference
genes (actin related protein 2/3 complex subunit 1B, ARCP1B;
ribosomal proteins S18, RSP18; and RSP19), using the Bestkeeper
software, and relative expression values were calculated using
Q-gene software, as detailed (45).
mAbs and Flow Cytofluorimetric Analysis
The following mAbs were used in this study: anti-CCR1
(R&D System, MAB 145-100, Minneapolis U.S.A.), anti-
CCR5 (R&D System, MAB 182-100 Minneapolis U.S.A.),
anti-CCR7 (R&D System, MAB 197-100 Minneapolis
U.S.A.), anti-CXCR1/IL-8 RA (R&D System, MAB 173-
100 Minneapolis U.S.A.), anti-CXCR3 (R&D System, MAB
160-100), anti-CXCR4 (R&D System, MAB 173-100), PE-
conjugated anti-CX3CR1 (Medical & Biological Laboratories
Co., LTD, D070-5), FITC-conjugated anti-CD3 (eBioscience,
11-0038-42 Thermofisher scientific, Waltham, Massachusetts,
Stati Uniti), PE-cyanine 7-conjugated anti-CD56 (Beckman
Coulter, A21692, Brea, California U.S.A.), PE-conjugated
anti-CD16 (130-106-704, Miltenyi Biotec Bergisch Gladbach,
Germany). The staining with the appropriate unlabeled mAbs
are followed by PE-conjugated isotype-specific goat anti-
mouse second reagent (Southern Biotechnology Associated,
Birmingham, AL, U.S.A.), and fluorescence was quantified on a
GalliosTM Flow Cytometer (Beckman Coulter, Brea, California
U.S.A.).
Multiplex ELISA Analyses
Freshly isolated NK cells were cultured for 20 h at 5X 105/mL
in flat bottom 96-well microtiter plates in the presence of the
following recombinant human cytokines: IL-2, IL-12+IL-18, or
IL-15+IL-18. The cytokine concentrations were: 100 U/mL IL-
2 (Proleukin, Novartis Basilea, Switzerland); 2.5 ng/mL IL-12
(Peprotech, 200-12 London, UK); 20 ng/mL IL-15 (Peprotech,
200-15 London, UK); 200 ng/mL IL-18 (Medical & Biological
Laboratories Co. LTD, B001-5, Japan). In the “PMA+IONO IL-
2” condition, NK cells were cultured in the presence of IL-2
for 26 h, and 100 ng/mL PMA (Phorbol 12-myristate 13 acetate,
SIGMA-Aldrich Saint Louis, Missouri, U.S.A.) and 500 ng/mL
IONO (Ionomycin, SIGMA-Aldrich, Missouri, U.S.A.) were
added to the cultures for the last 6 h. The cultures were performed
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in parallel under normoxic and hypoxic conditions (see above).
Culture supernatants were then collected and analyzed for their
cytokine content by MAGPIX R© System (Luminex R© xMAP R©
Technology, Merck Millipore, Germany).
Chemotaxis Assay
NK cells freshly isolated from peripheral blood and then cultured
for different time points (24, 48, and 96 h) with IL-2 under
hypoxic or normoxic conditions were seeded at 2.5 × 106/mL
in the upper chamber of a Transwell system (3mm pore size;
Corning Costar, 3415). 10% FBS RPMI 1640 medium alone or
supplemented with recombinant human CXCL12 [100 ng/mL]
(Peprotech, 300-28A), or CCL19 [0.3µg/mL], or CCL21
[0.6µg/mL] was added to the lower compartment. Cells were
allowed to migrate for 2 h at 37◦C under normoxic condition.
Cells migrated in the lower chamber were collected and counted
using the MACSQuant Analyzer (Miltenyi Biotec Bergisch
Gladbach, Germany) or analyzed with the GalliosTM Flow
Cytometer after surface double staining of CD56/CD16 markers.
Cells migrated in the lower chamber containing medium alone
(w/o chemokines) represented spontaneous migration due to
unspecific cell motility. Chemotactic response was assessed as
percentage of spontaneous migration and was calculated as
follows: (number of migrated cells in the presence of chemotactic
stimulus/number of migrated cells in the absence of stimulus)
× 100. The chemotactic response of CD56brightCD16dim/neg NK
cells to CCL19, CCL21, and CXCL12 was assessed as enrichment
of this specific cell subset withinmigrated cells and was calculated
as follows: CD56brightCD16dim/neg cell percentage within cells
migrated in response to chemokines/CD56brightCD16dim/neg cell
percentage within spontaneously migrated cells.
Statistical Analysis
Statistical analyses were performed using the Prism software
package (GraphPad Software). Data are expressed as the
mean± SEM of at least three independent experiments, unless
differently specified. Statistical significance was evaluated by two-
tailed paired Student’s t-test. A p < 0.05 (∗), <0.01(∗∗), or
<0.001(∗∗∗) was considered statistically significant.
RESULTS
Gene Expression Profile of Hypoxic NK
Cells
To obtain an overview of NK cell response to hypoxia, we
assessed the gene expression profile of NK cells isolated from
the PB of three independent healthy donors and cultured with
IL-2 for 16 or 96 h under hypoxic (1% O2) or normoxic
(20% O2) conditions. mRNA was individually hybridized to
human Affymetrix HG-U133 plus 2.0 GeneChips, obtaining
three biological replicates for each experimental condition. Raw
data were processed as described in the section Materials and
Methods. We used GSEA to determine the enrichment of the
published C2.CGP gene set collection (44) in the 16 and 96 h
transcriptomes of hypoxic NK cells (Hy-NK) as compared to
their normoxic counterparts. We selected 25 gene sets using
“hypoxia” and “hypoxia-inducible factor (HIF)” as keywords (see
section Materials and Methods for details). The list of gene
sets, their normalized enrichment score (NES), false discovery
rate q-values (FDR q-val), and nominal p-values (NOM p-val)
are reported in Table 1. Among selected gene sets, 20 were
significantly enriched in both Hy-NK cell transcriptomes (p
< 0.05; FDR q < 0.05), 1 and 3 additional gene sets were
specifically enriched in the 16 h (upregulated) and the 96 h
(downregulated) hypoxic transcriptomes, respectively, and only
1 gene set (upregulated) was not significantly enriched at either
time points. Representative 16 and 96 h plots showing clear
enrichment of the gene sets at the top or the bottom of the
ranked list are presented in Figure 1A for a visual inspection
of the GSEA results (46). These data demonstrate that gene
expression changes in Hy-NK cells follow a consensus hypoxia
transcriptional profile.
Gene transcriptional activation by hypoxia is mediated
primarily by HIF, a heterodimer of a constitutive HIF-1β subunit
and an O2-sensitive α-subunit (HIF-1α or HIF-2α) (32, 34).
Interestingly, some of the selected gene sets were from cells
undergoing HIF-1α or HIF-2α silencing (46). The reported sets
of down- or up-regulated genes were found inversely enriched in
the Hy-NK cell transcriptomes (Table 1—gene sets 1, 2, 19, 20—
and Figure 1B), suggesting that HIF-1α and HIF-2α and their
target genes could play an important role in NK cell response to
hypoxia.
Leading Edge Analysis (LEA) applied to the significantly
enriched gene sets allowed to define the subsets of hypoxia-
related genes with the highest impact on the enrichment
score (referred to as the leading edge subset) at 16 or 96 h
(Figure S1). These subsets include genes involved in glycolysis,
gluconeogenesis, and glucose transport (ALDOA, ALDOC,
ENO1, ENO2, GAPDH, GPI, HK1, HK2, LDHA, PDK1, PGK1,
SLC2A1, TPI1), non-glycolytic metabolism and ion transport
(P4HA1, P4HA2, PAM, VLDLR), apoptosis, stress response,
and proliferation (BNIP3, BNIP3L, CCNG2, DDIT3, EGLN1,
EGLN3, NDRG1), transcription and signaling activity (FOSL2,
JAK2, JUN, MXI1, SOCS2). These results extend to Hy-NK
cells the expression of a large cluster of hypoxia-related genes
previously identified in other cell types, including tumor and
immune cells (32, 34, 47–49).
Functional Assessment of Genes
Modulated by Hypoxia in NK Cells
To identify novel genes affected by hypoxia in NK cells, we
performed differential expression analysis of microarray data.
We filtered transcripts for a differential expression of at least
2-fold changes and a p ≤ 0.05. Using these selection criteria,
we identified a total of 1,474 transcripts that were significantly
modulated under hypoxic vs. normoxic conditions, with
expression changes ranging from 106-fold upregulation to 25-
fold downregulation (Table S1). The majority of differentially-
expressed transcripts were identified as unique genes named in
the GenBankTM, whereas the remaining transcripts were either
unnamed expressed sequence tags or hypothetical. As shown
by the Venn diagram in Figure 2A, 355 transcripts were up-
[179] or down-[176] regulated at both time points, whereas 374
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TABLE 1 | Hypoxia- and HIF-related gene sets enriched in the 16 and 96 h hy-NK cell transcriptomes.
GSEA terma 16h up 96h up
Sizeb NESc FDR q-vald Nom p-vale Size NES FDR q-val Nom p-val
ELVIDGE_HIF1A_TARGETS_DN 69 3.26 <0.001 <0.001 69 2.98 <0.001 <0.001
ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN 75 3.17 <0.001 <0.001 75 2.96 <0.001 <0.001
MENSE_HYPOXIA_UP 75 3.16 <0.001 <0.001 75 2.70 <0.001 <0.001
ELVIDGE_HYPOXIA_UP 130 3.06 <0.001 <0.001 130 2.78 <0.001 <0.001
ELVIDGE_HYPOXIA_BY_DMOG_UP 102 3.03 <0.001 <0.001 102 2.85 <0.001 <0.001
FARDIN_HYPOXIA_11 25 2.92 <0.001 <0.001 25 2.75 <0.001 <0.001
SEMENZA_HIF1_TARGETS 28 2.70 <0.001 <0.001 28 2.09 0.003 <0.001
LEONARD_HYPOXIA 33 2.67 <0.001 <0.001 33 2.55 <0.001 <0.001
KIM_HYPOXIA 18 2.62 <0.001 <0.001 18 2.02 0.005 <0.001
HARRIS_HYPOXIA 63 2.60 <0.001 <0.001 63 1.91 0.018 <0.001
GROSS_HIF1A_TARGETS_DN 17 2.59 <0.001 <0.001 17 1.75 0.064 0.006
WINTER_HYPOXIA_METAGENE 184 2.55 <0.001 <0.001 184 2.21 <0.001 <0.001
QI_HYPOXIA 107 2.47 <0.001 <0.001 107 2.01 0.005 <0.001
MANALO_HYPOXIA_UP 163 2.34 <0.001 <0.001 163 2.63 <0.001 <0.001
GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP 108 2.15 0.001 <0.001 108 1.96 0.01 <0.001
GROSS_HYPOXIA_VIA_ELK3_DN 125 1.52 0.1934 0.000 125 1.18 0.5 1
GSEA term 16h down 96h down
Size NES FDR q-val Nom p-val Size NES FDR q-val Nom p-val
MANALO_HYPOXIA_DN 236 −3.20 <0.001 <0.001 236 −3.34 <0.001 <0.001
ELVIDGE_HYPOXIA_DN 123 −2.84 <0.001 <0.001 123 −2.14 <0.001 <0.001
ELVIDGE_HIF1A_TARGETS_UP 56 −2.71 <0.001 <0.001 56 −1.88 0.003 <0.001
ELVIDGE_HIF1A_AND_HIF2A_TARGETS_UP 37 −2.62 <0.001 <0.001 37 −2.00 <0.001 <0.001
ELVIDGE_HYPOXIA_BY_DMOG_DN 49 −2.42 <0.001 <0.001 49 −2.12 <0.001 <0.001
GROSS_HYPOXIA_VIA_HIF1A_UP 60 −2.11 <0.001 <0.001 60 −1.81 0.007 <0.001
GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_DN 77 −1.57 0.0678 0.0051 77 −1.87 0.003 <0.001
GROSS_HYPOXIA_VIA_ELK3_UP 166 −1.43 0.1474 0.0118 166 −2.28 <0.001 <0.001
GROSS_HYPOXIA_VIA_ELK3_ONLY_DN 37 −1.85 0.004 <0.001
Microarray analysis was carried out on NK cells from 3 different donors cultured under normoxic (20% O2) and hypoxic (1% O2) conditions for 16 and 96 h. Differentially expressed
transcripts were ranked by level of hypoxia-mediated up- or down-regulation. The ranked gene lists were then compared with published gene sets for hypoxia-regulated genes or for
genes previously shown to be HIF targets in other cell types by GSEA.
aGene sets enriched in the GSEA analysis. Gene sets belonged to the C2.CGP collection of the MSigDB and were selected using the keywords “hypoxia” and “HIF” and filtering out
those having <15 probe sets and more than 250 probe sets. “Up” indicates genes enriched in the hypoxia transcriptomes (i.e., up-regulated in hypoxic NK cells); ”down" indicates
genes enriched in the normoxia transcriptomes (i.e., down-regulated in hypoxic NK cells).
bRelative number of probe sets in the gene sets.
cNormalized enrichment score of the gene sets. Gene sets are listed in decreasing order of NES.
dFDR q-value of the false discovery rate. Values ≤0.05 are considered acceptable.
eNOM p-value of the normalized enrichment score. Values ≤0.05 are considered significant.
(139 induced and 235 repressed) and 745 (334 induced and
411 repressed) transcripts were specifically modulated at 16 or
96 h, respectively. These results provide the first indication that
Hy-NK cell signature varies with the duration of exposure to
hypoxia.
To gain insights into the biological processes modulated by
hypoxia, we carried out a Gene Ontology (GO) enrichment
analysis on the lists of up- and down-regulated transcripts.
We identified 28 biological processes containing a statistically
significant enrichment of hypoxia-modulated genes (HMGs)
(Figure 2B). Most processes were represented at both time
points, although with variable HMG enrichment. Metabolism
and biosynthesis resulted as the most enriched processes (in
both up- and down-regulated genes), followed by response
to stimulus. Additionally, Hy-NK cell transcriptional
profile was related to regulation of apoptosis, and response
to stress, but also to cell proliferation, signaling, and
chromatine/chromosome organization. Certain processes,
including regulation of gene transcription and expression, and
cell differentiation, were selectively enriched in upregulated
genes, whereas processes related to cell cycle, cellular
component organization, and DNA replication and repair
were exclusively enriched in downregulated genes at both
time-points.
Importantly, different immune-related processes, including
immune system development/response, hemopoiesis,
leukocyte activation and differentiation, angiogenesis,
regulation of cell motility and communication, and
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FIGURE 1 | Gene Set Enrichment Analysis (GSEA) Plots for representative hypoxia- or HIF1α/2α-related gene sets in Hy-NK cell transcriptomes. The transcripts
identified by microarray analysis in NK cells were ranked by level of hypoxia-mediated up- or down-regulation. The ranked gene lists were then compared by GSEA
with previously published gene sets for hypoxia-regulated genes or for genes previously shown to be HIF targets in other cell types. (A) GSEA plots of representative
sets of up- or down-regulated genes from cells exposed to hypoxia (ELVIDGE_HYPOXIA_UP or _DN, respectively). (B) GSEA plots of representative sets of up- or
down-regulated genes from cells undergoing HIF-1α and HIF-2α silencing (Elvidge_HIF1A_and_HIF2A_TARGETS_UP or _DN, respectively). Note that in the case
HIF1α/2α-silencing the sets of up- or down-regulated genes resulted inversely enriched in the Hy-NK cell transcriptomes. The enrichment score is calculated by
walking down a list of genes ranked by their correlation with the phenotype, increasing a running-sum statistic when a gene in that gene set is encountered (each
black vertical line underneath the enrichment plot) and decreasing it when a gene that isn’t in the gene set is encountered. The enrichment score is the maximum
deviation from zero encountered in the walk.
immune effector processes, were enriched in a statistically
significant percentage of HMGs, suggesting regulatory
effects of hypoxia on NK cell-mediated immune
responses.
Characterization of Cytokine/Chemokine
and Receptor Gene Modulation in Hy-NK
Cells
As the effect of hypoxia on the NK cell capability of killing
target cells has been previously assessed (39), we focused our
analysis on genes involved in immunoregulation and migration.
The evaluation of immune-related gene clusters highlighted by
GO analysis led to the identification of 43 HMGs coding for
cytokines and chemokines, their receptors, and/or associated
signaling molecules (Table 2). Some of these genes (26) were
rapidly modulated by hypoxia (at 16 h time-point), while the
remaining genes (17) were modulated after longer exposure
(96 h).
Compared to their normoxic counterparts, Hy-NK cells
showed increased expression of genes coding for molecules with
a primary role in angiogenesis (VEGFA, VEGFB, ADM, SPP1,
FGF11) and promotion of inflammation or lymphocye cytotoxic
responses (SPP1, SPP2, VEGF,TNFRSF11A and 12A, IGFBP2,
FGFBP2, PTAFR), but also in apoptosis inhibition (IGF1R,
TNFRSF10D, 11A, and 12A), tumor progression (IGFBP2,
SPP1, MIF, PDGFD, TGFβ2, FGF11), and immunosuppression
(MIF and TGFβ2) (34, 37, 48, 50–55). On the other hand,
hypoxia inhibited mRNAs coding for cytokines and/or receptors
mainly involved in anti-tumor and anti-viral immune responses
including IFNγ, IFI30, IFI44, IL-17RC, IL1RL1, and various
components of the tumor necrosis factor (TNF) superfamily,
such as TNFα, LTA, LTB,TNFSF10,11,14, and TNFRSF18 (55–
63). The only exception was represented by the inhibition of
mRNA coding for LIF, a pleiotropic factor involved in the
regulation of inflammation.
The Hy-NK transcriptome was also characterized by the
differential modulation of genes coding for chemokines and
chemokine receptors (11, 15). Specifically, we observed hypoxia-
dependent upregulation of the mRNA for CXCL8 (which also
has proangiogenic properties) (11, 37, 52), and downregulation of
mRNAs for CXCL10, CCL3, and XCL1 (9, 11, 52, 64). Regarding
the chemokine receptors known to be important for NK cell
migratory activity mRNAs coding for CXCR4 and CX3CR1
were selectively up-regulated, whereas those coding for CXCR1,
CCR1, CCR5, and CXCR3 were downregulated.
Microarray results were validated by qRT-PCR analysis of a
subset of HMGs (17 belonging to the 16 h transcriptome and 9 to
the 96 h transcriptome). As shown in Figure 3 and Table 2 there
was almost full concordance between qRT-PCR and Affymetrix
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FIGURE 2 | Identification of genes significantly modulated by hypoxia in NK
cells by differential expression analysis. (A) Graphical representation of
transcripts differentially expressed in hypoxic vs. normoxic NK cells. The gene
expression profile of NK cells isolated from 3 different donors and exposed to
hypoxia for 16 h (top) or 96 h (bottom) was analyzed by microarray analysis, as
described in the section Materials and Methods. The Venn diagram depicts the
number of transcripts exhibiting ≥2 fold up- or down-regulation in hypoxic vs.
normoxic cells at the two time points. About 24% of differentially expressed
transcripts are common to the 16 and 96 h transcriptomes.
(Continued)
FIGURE 2 | (B) Functional assessment of hypoxia-responsive genes by GO
enrichment analysis. Unique genes showing at least 2-fold change in
expression levels between Hy-NK and NK cells were clustered into different
biological processes using the DAVID GO enrichment analysis. Based on this
classification scheme, genes were placed in more than one biological process
if more than one function of the encoded protein was established. The y-axis
shows the GO terms. The x-axis shows the percentage of genes within each
process relative to the total amount of genes belonging to that process: bars
on the right of the y axis represent upregulated genes; bars on the left of the y
axis represent downregulated genes. The blue columns represent genes
modulated at 16 h whereas the red column represent genes modulated at 96 h.
data with respect to the direction of the expression changes, with
the only exception of CX3CR1 whose upregulation by hypoxia
was not confirmed by qRT-PCR. For about half of validated
genes, the extent of modulation was also comparable to that
shown by microarray data, whereas it was higher for nine genes
and lower for three genes. Such discrepancies, however, are
consistent with previous findings showing that these techniques
can often differently estimate the extent of gene regulation
(42, 48).
A literature survey indicated that some of the HMGs in NK
cells were targeted by hypoxia in different cell types including
T lymphocytes (49), primary monocytes (48), monocyte-derived
macrophages (MDMs) (38, 65, 66), immature (i)DCs (67–70),
and mature (m)DCs (37, 68) (Table 2). In particular, MIF-
and VEGFA-coding genes were upregulated by hypoxia in
all the immune cell types analyzed, ADM and SPP1 were
increased in the innate immune cells, while CXCL8 and CXCR4
upregulation was reported in T cells and in some mononuclear
phagocyte populations. Other genes were variably modulated
depending on the analyzed cell type. To our knowledge, a
consistent part of the cytokine/chemokine- and receptor-coding
genes identified in Hy-NK cells have not been reported to
be modulated by hypoxia in other immune cell populations
analyzed.
Taken together, these data indicate that hypoxia can induce
a specific cytokine/chemokine and receptor gene signature in
NK cells with possible functional consequences. To assess this
possibility, we proceeded with the overall evaluation of the
effects of hypoxia on NK cell immune-regulatory and migratory
functions.
Effects of Hypoxia on NK Cell-Mediated
Release of Chemokines And Cytokines
To assess the effect of hypoxia on cytokine/chemokine release,
PB-NK cells were freshly isolated from additional donors and
cultured in the presence of IL-2 under hypoxic or normoxic
conditions. After 20 h, supernatants were collected and analyzed
by multiplex immunoassay for the content of IFNγ, TNFα,
CCL3, GM-CSF, CCL5, CXCL8, VEGF, and MIF (Figure 4),
namely those factors that are typically released by NK cells
(6, 12) and/or that were shown to be transcriptionally affected
in microarray analysis (Table 2). As shown in Figure 4A, upon
exposure to IL-2 NK cells released low levels of different factors,
including IFNγ, CCL3, GM-CSF, CCL5, andMIF. Under hypoxic
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FIGURE 3 | qRT-PCR validation of genes selected from the microarray profile. Total RNA from the NK cell preparations analyzed by microarray was subjected to
qRT-PCR for the expression of a subset of genes randomly selected from those up- or down-modulated at 16 h (A) or 96 h (B). Expression changes were evaluated in
relation to the values obtained for three reference genes, as detailed in the section Materials and Methods. Results are expressed as fold-changes (Hy-NK relative to
NK cells) and represent the mean of three determinations for each transcript. Positive values indicate that the mRNA levels of a specific gene was up-regulated,
whereas negative values indicate that the transcript was down-regulated. Genes are ordered by fold-change within each group.
conditions, release of IFNγ, CCL3, GM-CSF, and CCL5 was
decreased (although differences reached statistical significance
only for CCL3 and GM-CSF). Since IL-2 has typically limited
direct effects on cytokine release while it primes NK cells to
respond to other stimuli, we assessed the effect of hypoxia on NK
cells cultured for 20 h with IL-2 and stimulated for further 6 h
with PMA+ Ionomycin (PMA+IONO). As shown in Figure 4B,
an inhibitory effect on CCL3 and (slightly) on GM-CSF release
was induced by hypoxia also on PMA+IONO-stimulated NK
cells.
We next assessed the effect of hypoxia on NK cells
cultured with other classical NK-activating stimuli, such as
the monokines, IL-12, IL-15, and IL-18. In particular, we set
monokine combinations known to potently stimulate NK
cell cytokine secretion (i.e., IL-12+IL-18, and IL-15+IL-18).
As shown in Figure 4C, NK cells cultured in the presence of
IL-12 + IL-18 for 20 h released into the culture supernatant
very high amounts of IFNγ and moderate to low amounts of
CCL3, GM-CSF, TNFα, and CCL5. Hypoxia did not modify
significantly NK cell ability to release cytokines in response
to IL-12+IL-18, although a trend toward inhibition was
observed for CCL3, GM-CSF, and TNFα release. Compared
to IL-12+IL-18, IL-15+IL-18 stimulation induced lower
release of IFNγ and TNFα and higher secreted levels of
CCL3, GM-CSF, and CCL5 under normoxic conditions
(Figure 4D). Exposure to hypoxic conditions resulted in the
significant inhibition of IFNγ, TNFα, CCL3, GM-CSF, and CCL5
release.
We conclude from these data that hypoxia can differently
affect cytokine/chemokine release depending on the type of
stimulus. Specifically, it can modulate the release of only a few
cytokines/chemokines in NK cells cultured in the presence of
IL-2 or IL-2+PMA+IONO, exert a more general inhibition
of cytokine/chemokine secretion on NK cells exposed to
IL-15+IL-18, while it has no significant effects on NK cells
exposed to IL-12+IL-18.
Effect of Hypoxia on Chemokine Receptor
Expression
We next assessed whether hypoxia could modulate chemokine
receptor expression on NK cell surface. To this end, freshly
isolated PB-NK cells were cultured in the presence of IL-2 under
hypoxic or normoxic conditions and analyzed by flow cytometry
for the expression of CCR5, CCR7, CCR1, CX3CR1, CXCR1,
CXCR4, and CXCR3 immediately after isolation or after 24,
48, or 96 h of culture. Upon exposure to IL-2 (under normoxic
conditions), NK cells progressively down-regulated expression of
CXCR1, up-regulated that of CXCR3 and (transiently) that of
CXCR4, while they minimally modified the expression of CCR5,
CCR1, and CX3CR1. Hypoxia further significantly increased the
up-regulation of CXCR4 expression, slightly decreased CCR5
expression, while it did not substantially modify the expression
trend of CCR1, CX3CR1, CXCR1, and CXCR3 (Figures 5A,C).
The analysis of CCR7 on the whole PB-NK cell population
didn’t give meaningful data, as CCR7 expression is generally
confined to the small fraction of CD56bright cells (12, 17)
(Figures 5A,C). On the other hand, CD56bright NK cells showed
progressive decrease of CCR7 expression during culture with IL-
2. Hypoxia significantly reversed such effect sustaining CCR7
expression on CD56bright cells (Figures 5B,C). Remarkably, a
careful analysis of such NK cell subset revealed that also CXCR4
expression could be sustained by hypoxia in CD56bright cells
(Figures 5B,C).
Effects of Hypoxia on NK Cell Chemotaxis
Experiments were then carried out to assess whether hypoxia-
induced changes of CCR7 and CXCR4 expression could affect
specific chemotactic activity of NK cells. To this end, NK
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FIGURE 4 | Cytokine/chemokine release capability of NK cells exposed to hypoxia or normoxia. Cell-free supernatants from NK cells cultured in the presence of IL-2
(A), IL-2 and PMA+ionomycin (B), IL-12+IL-18 (C), IL-15+IL-18 (D) under normoxic (white columns) or hypoxic (gray columns) conditions were analyzed for 8
cytokine/chemokine content using the MAGPIX® System. Results are expressed as ng/ml and are the mean + SEM of 5 independent experiments. In (A,C,D), the
cells were cultured for 20 h in the presence of the indicated stimulating cytokines, in (B), the cells were cultured for 26 h in the presence of IL-2 with the addition of
PMA+ionomycin in the latter 6 h. * p < 0.05, ** p < 0.01.
cells cultured under normoxic or hypoxic conditions for 24,
48, and 96 h were analyzed in classical migration assays using
CCL19, CCL21 (CCR7 ligands) and CXCL12 (CXCR4 ligand) as
chemoattractants.
Given the peculiar distribution of CCR7 within the PB NK
cells, we analyzed whether CCL19 or CCL21 could induce
the preferential migration of the CD56brightCD16dim/neg cell
subset, resulting in the enrichment of such population within
migrated cells. Before performing this analysis, we evaluated
by FACS whether the percentage of CD56brightCD16dim/neg
cells could be modified over time under hypoxic or normoxic
culture conditions. As shown in Figure 6A the percentage
of CD56bright cells slightly decreased during culture under
normoxic conditions, while hypoxia preserved such a population
at the 24 and 48 h time points. This observation suggests that
hypoxia could contribute to increase the absolute number of
migrated CD56bright cells by preserving them over time. In
order to selectively evaluate the effect of hypoxia on specific
chemotactic properties of the cells, the chemotactic response to
chemokines was calculated as ratio of the CD56brightCD16dim/neg
cell percentages within cells migrated to specific chemokines
or spontaneously. Among NK cells that have been cultured
under normoxic conditions for 24 h, CD56bright cells were able
to migrate in response to both chemokines and enrich the
population of migrated cells. However, this ability progressively
disappeared at later culture time points. By contrast, Hy-NK cells
gave rise to higher enrichment of CD56bright cells within cells that
migrated in response to CCL19/21 andmaintained this capability
over time (Figures 6B,C).
The analysis of CXCR4-dependent chemotaxis indicated
that, overall, NK cells exposed to hypoxia were responsive to
CXCL12more thanNK cells cultured under normoxic conditions
(Figure 6D). Remarkably, this difference was more pronounced
when considering the CD56bright cell subset. Indeed, “hypoxic”
(but not “normoxic”) NK cells gave rise to enrichment of the
CD56bright cells within cells migrated to CXCL12 (Figures 6E,F).
These results were in line with the observation that under
hypoxia all CD56bright cells expressed CXCR4 at high levels while
CD56dim NK cells included a variable fraction of CXCR4neg cells
(Figure 5C).
Overall, these data demonstrate that hypoxia can sustain
CXCR4- and CCR7-dependent chemotactic response of NK cells
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FIGURE 5 | Effects of hypoxia on NK cell chemokine receptor expression. Freshly isolated PB-NK cells were cultured in the presence of IL-2 for 24, 48, or 96 h under
normoxic or hypoxic conditions and then analyzed by flow cytometry for surface expression of the indicated receptors. (A,B) The ratio between the MFI observed at
the indicated culture time points and that at t0 (i.e., on freshly isolated cells) is reported for each receptor. Horizontal dotted lines indicate no changes. White and gray
bars are referred to NK cells cultured under normoxic or hypoxic conditions, respectively. Data are the mean + SEM of 5 independent experiments. In (B) data on
CD56bright gated cells are reported for CCR7 and CXCR4 expression. (C) FACS profiles of a representative donor are shown. * p < 0.05.
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FIGURE 6 | Effect of hypoxia on chemotaxis of PB-NK cells and their CD56bright/CD56dim subset to CXCL12, CCL19, CCL21. PB-NK cells were cultured in the
presence of IL-2 for 24, 48, or 96 h under normoxic or hypoxic conditions and analyzed by FACS for the combined expression of CD56 and CD16 markers in order to
assess the percentage of the CD56brightCD16dim/neg cells before migration (A). Cells were then assessed for chemotaxis to the indicated chemokines under
normoxic conditions for 2 h. Migrated cells were collected from the lower migration chamber compartments and counted or analyzed by FACS for the combined
(Continued)
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FIGURE 6 | expression of CD56 and CD16 markers. The specific chemotactic response of CD56brightCD16dim/neg NK cells to CCL19, CCL21 (B), and CXCL12 (E)
was assessed as enrichment of this cell subset within migrated cells. The enrichment was calculated as fold increase of the CD56brightCD16dim/neg cell percentage
within cells migrated to specific chemokines as compared to the CD56brightCD16dim/neg cell percentage within spontaneously migrated cells (see section Materials
and Methods for details). (C,F) Representative experiments showing the enrichment of CD56brightCD16dim/neg NK cells within cells migrated in response to CCL19,
CCL21 (C) or CXCL12 (F) as compared to cells that spontaneously migrated in the lower compartment in the absence of stimuli (CTR). (D) Specific chemotactic
response to CXCL12 of the whole PB-NK cell population cultured under normoxic or hypoxic conditions. In (B,D,E) white and gray bars indicate data from NK cells
cultured under normoxic or hypoxic conditions, respectively and represent the mean ± SEM of 6 independent experiments. * p < 0.05, ** p < 0.01.
to specific chemokines, such as CXCL12, CCL19, or CCL21,
and favor the recruitment of CD56bright cells, suggesting that a
hypoxic environment may influence the extent and the nature of
the NK cell infiltrate in different types of tumors.
DISCUSSION
In the present study we analyze the global effects of hypoxia on
NK cells, which are among the most potent immune effectors
available to the host for the control of tumor development
and progression (1, 2, 6). We first provide the transcriptional
overview of the response of IL-2-primed NK cells to short-term
(16 h) and prolonged (96 h) hypoxia, demonstrating that Hy-
NK cells are functionally reprogrammed through the differential
expression of a large number of genes implicated in various
aspects of NK cell biology, including immunoregulation and
migration. Then, we document hypoxia influence on the
chemotactic properties of specific NK cell subsets and on NK cell
ability to release cytokines and chemokines, providing important
clues on the effective role of the O2 tension in determining the
composition and the function of the NK cell infiltrate in tumor
lesions.
So far, one transcriptional study describing how hypoxia
could influence the cytokine-mediated activation of NK cells
has been done for IL-15, while no data were available on IL-
2, although this factor represents the most known and studied
priming cytokine for NK cells. As assessed by GSEA, gene
expression changes observed upon NK cell exposure to 1% O2
conditions follow a consensus hypoxia transcriptional profile.
Several hypoxia-related and HIF-1α/HIF-2α target gene sets
defined in previous studies are, in fact, significantly enriched in
both the 16 and the 96 h Hy-NK transcriptomes. Moreover, we
find enrichment of genes involved in glycolysis, gluconeogenesis,
glucose transport, non-glycolytic metabolism, and ion transport,
which is a common feature of hypoxic cells of different type,
origin, and functional state being essential to compensate for the
inhibition of oxidative metabolism and the malfunctioning of
O2-dependent enzymes occurring under conditions of reduced
oxygenation (32, 34, 47–49).
GO clustering of HMGs in NK cells indicates that hypoxia
can modulate several biological processes and suggests that NK
cells reaching hypoxic tumor areas may deeply change their
mode to respond to stimuli or exert their functions. Processes
related to metabolism and biosynthesis, response to stimuli,
regulation of apoptosis and response to stress, cell proliferation,
and signaling appear to be all affected by hypoxia suggesting
that NK cells may modulate a wide range of functions in a
hypoxic environment. In particular, the coordinated enrichment
of down- or up-regulated genes in specific processes, such
as cell cycle, DNA replication and repair, cellular component
organization, regulation of gene transcription and expression,
indicates that NK cells can moderate their biosynthetic and
proliferative capabilities in response to decreased O2 tension.
Noteworthily, among HMGs we identified a significant
cluster of immune-related genes, 43 of which coding for
cytokines, chemokines, and their receptors. Several of these
cytokine/chemokine-coding genes have not been previously
reported to be affected by hypoxia in NK cells, although
some of them are known from the literature to be modulated
in other immune cells either exposed to short-term hypoxia
(typically 8–24 h) (48, 49, 65, 66, 70, 71) or generated under
conditions of long-term hypoxia (37, 38, 47, 67–69). On the
other hand, some genes appear to be modulated uniquely in
NK cells, as they have never been characterized in terms of
responsiveness to hypoxia in other immune cells. These findings
indicate that hypoxia regulates the expression of genes coding for
cytokines/chemokines on different immune cell populations, but
it can also activate a distinct transcriptional profile in NK cells.
The data on immune-related HMGs give some hints on
how NK cells may be functionally skewed in a hypoxic
microenvironment. The early downregulation of genes coding
for IFNγ and for several members of the TNF family, such
as TNFα, LTA, LTB, TNFSF14, TNFSF10, and TNFSF11, is of
particular interest given the role of these molecules in triggering
tumor immunogenicity, decreasing tumor proliferation and
angiogenesis, and favoring apoptotic tumor cell killing. Likewise,
the downregulation of genes coding for TNFRSF18 and IL1RL1
may be crucial, as these molecules act by enhancing IFNγ
secretion and potentiating NK cell expansion and response
to tumors (62, 63). Consistently, hypoxia also induces the
up-regulation of genes coding for important proangiogenic,
protumorigenic, prometastatic, and/or immune suppressive
factors, namely VEGFA,B, SPP1,2, CXCL8, MIF, TGFβ2, and
PDGFD (11, 34, 37, 48, 50–54). Finally, it is remarkable the
modulation of genes coding for chemokines and chemokine
receptors.
Collectively, our gene expression analysis suggests a major
effect of hypoxia on the immunomodulatory functions and
the chemotactic properties of NK cells. These aspects are not
trivial, as the nature and the function of the NK cell infiltrate
at the tumor site, as well as the tissue distribution of specific
NK cell subsets, can influence the prognosis of different tumor
types (11, 12, 28, 29). For this reason we decided to investigate
in detail the effect of hypoxia on these specific functions of
NK cells: cytokine/chemokine release and migration to specific
stimuli.
Frontiers in Immunology | www.frontiersin.org 19 October 2018 | Volume 9 | Article 2358
Parodi et al. Hypoxia Effects on Human NK
Multiplex ELISA analysis of NK cell culture supernatants
partly confirmed the indications obtained by the gene chip
analysis, showing that, indeed, hypoxia can limit the ability of
NK cells to release different factors involved in the host response
to the tumor, such as IFNγ, TNFα, GM-CSF, CCL3, and CCL5.
These factors are endowed with antitumor activity and/or can
induce recruitment, differentiation, proliferation, and activation
of APCs, Th1 lymphocytes, and NK cells (9, 11, 72, 73). Hypoxia
appears to variably affect cytokine release, depending on the type
of NK cell stimulation. Indeed, its inhibitory effect is particularly
evident on NK cells exposed to the monokine combination, IL-15
+ IL-18, while it does not reach statistical significance in case of
IL-12 + IL18 stimulation. We couldn’t find any transcriptional
modulation of genes coding for IL-12, IL-15, IL-18, or IL-
2 receptor subunits, suggesting that the differential effect of
hypoxia on the various stimuli may involve other mechanisms
such as the interference with specific signaling pathways.
That hypoxia could differentially modulate NK cells under
differentmonokine stimuli is important both because stimulatory
monokines can be released by immune cells in inflamed tissues
and also in view of the recent lines of research aimed at the
definition of effective monokine combinations in NK-based
immunotherapy (2, 17, 74). Notably, the hypoxia-related factors
CXCL8, VEGF, and MIF were not (or poorly) released by both
“normoxic” and “hypoxic” NK cells, although they were induced
by hypoxia at the mRNA level. This discrepancy suggests that
target-specific translational regulation (49, 67) can shape NK cell
response to hypoxia, giving rise to unique functional profiles.
The fact that hypoxia fails to induce CXCL8, VEGF, and MIF
secretion by NK cells has also been reported in a recent study
by Velasquez et al. (41). In that study, however, in contrast to
our present data, exposure to hypoxia could induce little, but
significant, secretion of CCL3, CCL4, and CCL5. The discrepancy
between our and their results may probably be ascribed to the
different experimental protocols used, in particular with regard
to the priming cytokines (IL-2, IL-12+IL-18, or IL-15+IL-18 in
our study vs. IL-15 alone in that of Velasquez) and the time and
duration of priming (the whole 20 h culture period in our study
vs. the final 6 h culture in the Velasquez study).
Evaluation of chemokine receptor surface expression reveals
that hypoxia can significantly increase the expression of CXCR4
receptor on a large fraction of PB-NK cells, suggesting that
changes in the levels of O2 tension within tissues may
significantly influence NK cell trafficking (11). The CXCL12-
CXCR4 axis represents one of the mechanisms responsible
for tumor spread, driven by pro-metastatic CXCR4+ tumor
cells. In addition, CXCL12 expressed by Tumor Associated
Fibroblasts (TAF) and tumor cells has been demonstrated to play
an important role in favoring tumor growth and progression
in primary lesions. Thus, sustained CXCR4 expression in NK
cells may be important for reaching and infiltrating certain
metastatic niches (for example in the bones) and also primary
tumors. In this context, in a model of NKp46-targeted HIF1α
KO mice, it has been recently shown that NK cells can reach
hypoxic tumor tissues, influence angiogenesis, tumor growth,
and metastasis spread in a HIF1α-dependent fashion (75).
Remarkably, our data indicate that, in humans, hypoxia can
differently affect two functionally distinct NK cell subsets. We
observed that hypoxia-induced CXCR4 up-regulation involved
the whole CD56bright NK cell population, while it affected only
a fraction (even if large) of CD56dim cells. Accordingly, hypoxic
NK cells that migrated to CXCL12 showed an enrichment of such
CD56bright cell subset. Along this line, hypoxia also increased
CCR7 expression on CD56bright cells, enhancing their selective
migration in response to CCL19 and CCL21. The CCL19/21-
CCR7 axis drives metastatic spread to Lymph Nodes but also
promotes homing of specific leukocyte subsets. In addition, the
CCL21-CCR7 interaction may be effective at the tumor site
(76, 77). Overall, our data suggest that hypoxia can intervene
in the recruitment of specific NK cell subsets at the site of both
primary tumor and metastasis and offer new hints to explain
the relative high frequencies of poorly cytotoxic CD56bright cells
observed within the NK cell infiltrate of several tumors (29–
31). Of course these findings, although suggestive, must be
considered within the rich network of factors that regulates
lymphocyte trafficking in different tumor sites. As an example,
it has been recently described the complex correlation between
the chemokine receptor pattern of different T lymphocyte subsets
and the control of metastasis in specific sites (78). Also NK cells
can respond to multiple chemokines that can be variably released
in different tumor sites. In this context, it is worth-noting that
NK cells can amplify their recruitment at the tumor site by killing
tumor cells and inducing release of chemiotactic HMGB1 (79).
Various escape mechanisms induced by the tumor hypoxic
environment have been documented in the last years, most
relying on the suppression of different immune cell types,
others involving the editing of the tumor cell targets or the
tumor microenvironment (23, 33, 38, 47, 80–85). However, only
few studies were focused on NK cells. This report represents
the first comprehensive transcriptome analysis of human Hy-
NK cells, which defines a wide array of hypoxia-modulated
immunological genes. Remarkably, our study also describes
how hypoxia can influence the type and function of NK
cells reaching hypoxic tissues, thus providing new elements
useful to design improved NK cell-based immunotherapeutic
strategies.
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